Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Elicio Therapeutics logo — Lymph-Node Targeted Immunotherapies

Elicio Therapeutics

Lymph-Node Targeted Immunotherapies

Founded 2011 United States Boston, United States 47 employees IPO Total: $206.86M Biotechnology, Health Care +2

General Information

Company Name Elicio Therapeutics
Founded Year 2011
Location United States Boston, United States
Founders / Decision Makers
Team member
Employees 47
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage IPO
Social

BounceWatch is an independent company data service, not affiliated with Elicio Therapeutics. To contact Elicio Therapeutics, visit elicio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Elicio Therapeutics compare?

A PDF of Elicio Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Elicio Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company founded in 2011, with a focus on advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of aggressive cancers. The company's slogan "Orchestrating the immune response to defeat cancer & infectious diseases" aptly summarizes its mission. Elicio leverages its expertise in immunology and immunotherapy to harness the natural power of the immune system, utilizing the innovative Amphiphile (“AMP”) technology. This technology enables the targeted delivery of therapeutic payloads directly to the lymph nodes, enhancing the immune system’s cancer-fighting capabilities. Through its research and development efforts, Elicio aims to optimize the lymph nodes’ natural ability to educate, activate, and amplify cancer-specific T cells, crucial for recognizing and eliminating tumor cells. The company's R&D pipeline includes off-the-shelf therapeutic cancer vaccines, namely ELI-002 targeting mKRAS-driven cancers, ELI-007 targeting BRAF-driven cancers, and ELI-008 targeting p53 hotspot mutations. Positioned at the core of the immune response, Elicio's AMP technology is designed to enhance the magnitude, potency, quality, and durability of the immune response to drive antitumor activity. Elicio Therapeutics received a significant $7.00M post-IPO equity investment from GKCC on 22 December 2023. The company operates in the biotechnology, healthcare, and pharmaceutical industries, with its headquarters in the United States. Overall, Elicio Therapeutics' innovative approach and promising pipeline position the company at the forefront of developing impactful immunotherapies for challenging cancers and infectious diseases. For more information, please visit www.elicio.com.

Business keywords: immunotherapy, cancer treatment, vaccine development, immune response modulation, lymphatic system targeting, Amphiphile platform, precision medicine, oncology research, biological engineering, materials science, drug development, preclinical studies, immune system enhancement, cellular immunology, biomedical technology

Funding Rounds & Investors (17)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $10.00M -
01 Jan 2025
Post-IPO Equity $20.00M 1
GKCC
01 Aug 2024
Private Placement VC $7.00M 1
GKCC
01 Dec 2023
Grant $2.60M 1
Gastro-Intestinal Research Foundation
01 Sep 2023
IPO $10.00M 1
BioMed Partners
BioMed Partners
01 Jan 2023
Grant $2.80M -
01 Sep 2022
Series C $37.00M -
01 May 2022
Debt Financing $2.00M -
01 Oct 2021
Series B $40.00M -
01 Feb 2021
Early VC Undisclosed -
01 Oct 2020

View All 17 Funding Rounds

Elicio Therapeutics Alternatives & Competitors

View All Alternatives
Elicio Therapeutics vs
Tolerx, Inc.
Tolerx, Inc. United States

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candi...

Venture round
9 employees
Biotechnology, Health Care
Compare Elicio Therapeutics vs Tolerx, Inc.
Elicio Therapeutics vs
Alloplex Biotherapeutics Inc
Alloplex Biotherapeutics Inc United States

A robust cellular therapeutic platform for treating cancer.

Series A
5 employees
Biopharma, Biotechnology
Compare Elicio Therapeutics vs Alloplex Biotherapeutics Inc
Elicio Therapeutics vs
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. United States

Delivering a cancer-free future

Post-IPO Equity
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About Elicio Therapeutics

Lymph-Node Targeted Immunotherapies
Elicio Therapeutics was founded in 2011.
Elicio Therapeutics is headquartered in Boston, United States.
Elicio Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on immunotherapy, cancer treatment, vaccine development and immune response modulation.
Elicio Therapeutics has approximately 47 employees.
Elicio Therapeutics has completed 17 funding rounds, raising a total of $206.86M. The latest funding stage is IPO.
Top alternatives and competitors to Elicio Therapeutics include Tolerx, Inc., Alloplex Biotherapeutics Inc, TransCode Therapeutics, Inc., HRAIN BIOTECHNOLOGY, Coley Pharmaceutical Group. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Elicio Therapeutics and Tolerx, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Elicio Therapeutics, https://bouncewatch.com/company/elicio-therapeutics, updated 4 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout